# A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH

Study · id `cardio:ct-nct02284737` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02284737](<https://clinicaltrials.gov/study/NCT02284737>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02284737

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 100 participants.

## Technical summary

Registry record NCT02284737. Randomized; single masking; primary purpose treatment. Start 2014-11-28 (actual); primary completion 2021-07-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02284737, source copy `cardio:ctgov-nct02284737-2024-02-20`, retrieved 2026-10-31)
- Started: 2014-11-28 (actual) (ClinicalTrials.gov record NCT02284737, source copy `cardio:ctgov-nct02284737-2024-02-20`, retrieved 2026-10-31)
- Primary completion: 2021-07-30 (actual) (ClinicalTrials.gov record NCT02284737, source copy `cardio:ctgov-nct02284737-2024-02-20`, retrieved 2026-10-31)
- Completion: 2021-07-30 (actual) (ClinicalTrials.gov record NCT02284737, source copy `cardio:ctgov-nct02284737-2024-02-20`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT02284737, source copy `cardio:ctgov-nct02284737-2024-02-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02284737-2024-02-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
- Acronym: PADN-PAH
- Condition: Pulmonary Arterial Hypertension
- Intervention (Procedure): PADN
- Intervention (Procedure): sham PADN
- Intervention (Drug): Sildenafil
- Lead sponsor: Nanjing First Hospital, Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Nanjing First Hospital, Nanjing Medical University (`cardio:org-nanjing-first-hospital-nanjing-medical-university`)

## Provenance

Content hash: c2df338e8f5fa16a3de6bfb77952c1ab220ff4708e50d0ce24ab4d0e0ee9e4f1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
